What is the recommended dose of unfractionated heparin for prophylaxis and therapeutic anticoagulation?

Unfractionated Heparin Dosing

For therapeutic anticoagulation in venous thromboembolism, use weight-based dosing with an 80 units/kg IV bolus followed by 18 units/kg/hour continuous infusion, targeting an aPTT of 1.5-2.5 times control. 1

Therapeutic Anticoagulation Dosing

Venous Thromboembolism (VTE) Treatment

Intravenous Administration:

• Initial bolus: 80 units/kg IV (or fixed 5,000 units) 1
• Continuous infusion: 18 units/kg/hour (or minimum 32,000 units/24 hours) 1
• Target aPTT: 1.5-2.5 times control (equivalent to anti-Factor Xa level 0.30-0.70 U/mL) 2, 3

The American College of Chest Physicians guidelines emphasize that weight-based dosing achieves therapeutic anticoagulation faster than fixed dosing, with significantly lower recurrent thromboembolism rates. 1 The FDA label confirms these regimens for continuous IV infusion at 20,000-40,000 units/24 hours. 3

Subcutaneous Administration (Alternative):

• Option 1: 5,000 units IV bolus, then 250 units/kg SC twice daily 1
• Option 2: 333 units/kg SC initial dose, then 250 units/kg SC twice daily 1

Acute Coronary Syndromes

Unstable Angina/Non-STEMI:

• Bolus: 60-70 units/kg (maximum 5,000 units) 1
• Infusion: 12-15 units/kg/hour (maximum 1,000 units/hour) 1

STEMI with Fibrinolytic Therapy:

• Bolus: 60 units/kg (maximum 4,000 units) 1
• Infusion: 12 units/kg/hour (maximum 1,000 units/hour) 1

The lower doses for acute coronary syndromes reflect increased bleeding risk when combined with fibrinolytics or GP IIb/IIIa inhibitors. 2, 1

Prophylactic Dosing

Standard VTE Prophylaxis

Fixed-dose regimen:

• 5,000 units SC every 8-12 hours 2, 3
• Administer 2 hours before surgery, then continue every 8-12 hours for 7 days or until fully ambulatory 3

Critical caveat: Standard prophylactic dosing (5,000 units SC twice daily) is less effective than three-times-daily dosing or low-molecular-weight heparins. 4 Evidence shows 5,000 units SC three times daily provides superior VTE prevention compared to twice-daily dosing (relative risk 0.28 vs 0.4). 4

Pediatric Dosing

Initial bolus: 75-100 units/kg IV over 10 minutes 3

Maintenance infusion:

• Infants (<2 months): 25-30 units/kg/hour (average 28 units/kg/hour) 3
• Children >1 year: 18-20 units/kg/hour 3
• Target aPTT: 60-85 seconds (anti-Factor Xa 0.35-0.70) 3

Use preservative-free formulations in neonates and infants. 3

Monitoring Requirements

Initial monitoring:

• Check aPTT at baseline, then every 4 hours during continuous infusion until stable 3
• For intermittent IV dosing, check before each injection 3
• For SC dosing, check 4-6 hours after injection 3

Ongoing monitoring:

• Platelet counts, hematocrit, and occult blood in stool throughout therapy 3
• Adjust doses to maintain aPTT 1.5-2.5 times control 2, 1

Important pitfall: Achieving therapeutic aPTT within 24 hours is critical—patients with acute pulmonary embolism who reached therapeutic levels faster had lower in-hospital and 30-day mortality. 1

Special Populations

Obesity

Lower weight-adjusted doses may be required in obese patients to achieve target anticoagulation. 5 Body mass index is the only significant covariate affecting heparin response after weight-based dosing. 5 Despite this, many obese patients still require dose adjustments, as only 49% achieve target ACT with initial recommended bolus doses. 5

Low Body Weight (≤50 kg)

Consider reduced prophylactic dosing (enoxaparin 30 mg daily or heparin 5,000 units every 12 hours SC) to minimize bleeding risk while maintaining VTE protection. 6

Cardiovascular Surgery

• Initial dose: Minimum 150 units/kg 3
• For procedures <60 minutes: 300 units/kg 3
• For procedures >60 minutes: 400 units/kg 3

Key Clinical Pitfalls

Medication errors: Fatal hemorrhages have occurred from confusing high-concentration vials (10,000 units/mL) with catheter lock flush vials—always verify vial strength before administration. 3

Inadequate initial dosing: Fixed-dose regimens result in higher recurrence rates than weight-based protocols. 1 The evidence strongly supports aggressive initial dosing to achieve therapeutic levels rapidly.

Route-dependent bioavailability: Subcutaneous administration has reduced bioavailability compared to IV infusion, requiring higher total daily doses (35,000-40,000 units SC vs 32,000 units IV). 2, 1

Bleeding risk factors: Risk increases with supratherapeutic clotting times, age >60 years, recent surgery/trauma, concomitant fibrinolytics or GP IIb/IIIa inhibitors, and multiple comorbidities. 1